market access

News

NICE rejects Novartis' CAR-T in adult lymphoma

NICE has said Novartis’ CAR-T therapy Kymriah cannot be funded by the NHS in adults with an aggressive form of lymphoma, calling for further discussions to get the drug on to the market.

News

UK 'less interesting' to pharma because of Brexit - Roche CE...

Big pharma less likely to invest in UK, says Severin Schwan

News

Roche calls for talks after NICE rejects drug for progressiv...

Roche has said it will continue with talks with UK health officials to bring its multiple sclerosis drug Ocrevus to NHS patients with primary progressive disease, after NICE said it was not

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Market Access

Realising the biotech promise: addressing the path to market

Overview Now more than ever before, biotech is the engine for innovation in medicine, finding, creating and delivering ground-breaking treatments to patients.

News